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ABSTRACT
Aims To estimate the effectiveness of pregnancy smoking cessation support delivered by shortmessage service (SMS) text
message and key parameters needed to plan a deﬁnitive trial. Design Multi-centre, parallel-group, single-blinded,
individual randomized controlled trial. Setting Sixteen antenatal clinics in England. Participants Four hundred and
seven participantswere randomized to the intervention (n=203) or usual care (n=204). Eligiblewomenwere< 25weeks
gestation, smoked at least one daily cigarette (> 5 pre-pregnancy), were able to receive and understand English SMS texts
and were not already using text-based cessation support. Intervention All participants received a smoking cessation
leaﬂet; intervention participants also received a 12-week programme of individually tailored, automated, interactive,
self-help smoking cessation text messages (MiQuit). Outcome measurements Seven smoking outcomes, including
validated continuous abstinence from4weeks post-randomization until 36weeks gestation, design parameters for a future
trial and cost-per-quitter. Findings Using the validated, continuous abstinence outcome, 5.4% (11 of 203) of MiQuit
participants were abstinent versus 2.0% (four of 204) of usual care participants [odds ratio (OR) = 2.7, 95% conﬁdence
interval (CI) = 0.93–9.35]. The Bayes factor for this outcome was 2.23. Completeness of follow-up at 36 weeks gestation
was similar in both groups; provision of self-report smoking data was 64% (MiQuit) and 65% (usual care) and abstinence
validation rates were 56% (MiQuit) and 61% (usual care). The incremental cost-per-quitter was £133.53 (95%
CI = –£395.78 to 843.62). Conclusions There was some evidence, although not conclusive, that a text-messaging
programme may increase cessation rates in pregnant smokers when provided alongside routine NHS cessation care.
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INTRODUCTION
Smoking in pregnancy is associated strongly with
pregnancy complications, including miscarriage [1],
spontaneous preterm birth [2], small for gestational age
[2] and stillbirth [3,4]. Smoking in pregnancy also
perpetuates health inequalities; rates are approximately
ﬁve times higher in the most deprived women compared
with the least deprived [5–7] and children born to smokers
have an increased risk of becoming smokers themselves
[8,9]. Systematic review evidence shows that behavioural
smoking cessation interventions reduce the risks of preterm
birth and low birth weight by approximately 18% [10].
Structured self-help support helps pregnant smokers to
stop [11,12]. Mobile phone text messaging is a simple way
of providing self-help support and is effective for non-
pregnant smokers [13]. However, many aspects of ‘generic’
text messaging cessation systems are unlikely to be
appropriate in pregnancy. Available generic programmes
make no mention of pregnancy [13], which for most
pregnant smokers is the main reason they try quitting
[14], and effective behavioural support for pregnant
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smokers is typically strongly pregnancy-orientated [10].
Consequently, pregnant smokers may ﬁnd much of the
behavioural support delivered by generic programmes
irrelevant, reducing its impact and perhaps even being
counterproductive [15]. Even more importantly, available
‘generic’ programmes provide some advice and support
that potentially could be harmful in pregnancy. For
example, use of nicotine replacement therapy (NRT) is
encouraged without consideration of pregnancy-speciﬁc
risks, and generic advice on keeping ﬁt and weight gain
after quitting are quite different from what might be
appropriate in pregnancy.
To maximize the potential of self-help support for
helping pregnant smokers to stop, we have developed an
individually tailored short message service (SMS) text
messaging intervention speciﬁcally for pregnant smokers,
called MiQuit. This process followed the Medical Research
Council framework for developing and evaluating complex
interventions [16] and was informed by extensive
qualitative work with pregnant smokers [17]. MiQuit can
be used by all pregnant smokers, as the support it provides
is tailored to a woman’s level of motivation to quit. A
randomized controlled trial (RCT) (n = 207) demonstrated
that randomization to MiQuit or routine care is feasible,
that women ﬁndMiQuit highly acceptable and that MiQuit
is likely to encourage cessation until at least mid-
pregnancy [18]. This feasibility trial provided the best
available estimate for MiQuit efﬁcacy, albeit for a relatively
brief cessation period; we believed cessation at the end of
pregnancy would be a more appropriate outcome for a
deﬁnitive trial, as this would result in maximal beneﬁts
for the fetus. As MiQuit is a cheap intervention with
potential for wide dissemination, we anticipated that even
a 1–2% absolute effect on smoking cessation in pregnancy
could prove clinically important and cost-effective and the
imprecise efﬁcacy estimate we had obtained suggested that
an impact of this size was potentially attainable.
Consequently, we planned a full trial to detect such an
effect on smoking cessation until the end of pregnancy,
and estimated this could require 3–4000 participants. This
large, pilot RCT was conducted to investigate the feasibility
of undertaking a much larger multi-centre RCT in UK
National Health Service (NHS) settings to determine
whether or not MiQuit can impact upon cessation
throughout pregnancy. The current trial would also
provide estimates of effectiveness and cost-effectiveness,
with the latter enabling comparisons with other cessation
interventions.
METHODS
Design
This was a multi-centre, two-arm, parallel group, single-
blind, individually randomized controlled trial.
Study population
Participants were recruited from 16 English NHS hospital
antenatal clinics between February and September 2014.
They were aged 16 years and over, less than 25 weeks
pregnant, had smoked at least ﬁve cigarettes daily before
pregnancy and at least one per day at enrolment, able to
understand written English and owned a mobile phone
with text messaging functionality. Participants already
using text message-based smoking cessation support were
excluded.
Study protocol and interventions
The study protocol was approved by Nottingham 1
Research Ethics Committee (Ref.:13/EM/0427) and
subsequently published [19].
Usual care
Participants were given a standard NHS booklet on
smoking cessation for mothers-to-be (Supporting
information, Appendix S1) and could access smoking
cessation information, advice or support for stopping
smoking offered as part of routine antenatal care.
Intervention
Two days after enrolment, in addition to the booklet and
usual care, intervention participants started to receive
MiQuit: an automated 12-week advice and support
programme for quitting smoking in pregnancy delivered
by SMS text message. MiQuit objectives are informed by
Social Cognitive Theory [20], Perspectives on Change
Theory (Borland, 2000, unpublished work), the
Elaboration Likelihood Model of Persuasion [21] and
several additional cognitive determinants of quitting
smoking in pregnancy [18]. It uses 14 participant
characteristics to tailor support individually [22]. Tailoring
characteristics include gestation, motivation to quit, the
hardest situation to avoid smoking, cessation self-efﬁcacy,
cigarette dependence and partner’s smoking status. ‘Push’
support (i.e. automated support sent to participants’
phones) is delivered according to a delivery schedule (0, 1
or 2 daily texts). Push message frequency is highest in
the ﬁrst 4 weeks. Push support includes motivational
messages, advice about quit attempt preparation,
managing cravings and withdrawal, dealing with trigger
situations and preventing lapses, information about fetal
development and how smoking affects this (see Supporting
information, Appendix S2 for example messages and
tailoring variables). Users can alter support frequency by
texting the keywords MORE or LESS, and are encouraged
to set and send a quit date to MiQuit to enable them to
receive additional support orientated around when their
quit attempt begins. At 3 and 7weeks into the programme,
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users are asked to respond to texts asking about smoking in
the previous 3 days, so that subsequent support is further
tailored to smoking behaviour [22]. Additionally, system
users can ‘pull’ on-demand support for combatting
cravings or temptation to smoke by texting HELP and seek
advice on returning to abstinence after a lapse by texting
SLIP. Alternatively, texting QUIZ provides a multiple-choice
message trivia game designed to distract users from
smoking. Support can be discontinued by texting STOP.
More detailed information about the development and
structure of the intervention can be found elsewhere
[18,22].
Enrolment, randomization and blinding
Research midwives (RMs) identiﬁed potential participants
in antenatal clinics via their clinic notes or a screening
questionnaire, and interested women were provided with
participant information sheets. RMs sought written
consent, but if time was insufﬁcient, contact details were
requested instead and verbal consent was sought later in
a phone call from the RM or a researcher from the trial
coordination team. Next, baseline data were collected
and, after this was entered onto a web-based database,
participants were randomized individually to usual care
or the MiQuit intervention in a 1 : 1 ratio using the
Nottingham Clinical Trials Unit web-based system, with
both the RM or researcher and the participant remaining
masked to allocation. Randomization used a computer-
generated pseudo-random code with random permuted
blocks of randomly varying size, and stratiﬁcation was by
study site and gestation (<16 versus ≥16 weeks).
Following randomization, unblinded trial team members
sent arm-speciﬁc information packs to participants, which
included the usual care booklet. Those dispatching packs
were not involved in collecting follow-up data. Trial staff
involved in follow-up remained unaware of participants’
treatments until questions on the intervention were asked
at the end of the study, after smoking outcome data had
been collected.
Data collection
Baseline data included contact details, age, highest
qualiﬁcation, postcode to enable matching to Index of
Multiple Deprivation (IMD) scores [23], ethnicity (based
on UK Census categories), gestation, pre-pregnancy
smoking rate, heaviness of smoking index [24], strength
and frequency of urges to smoke [25], whether a quit date
had been set, intention to quit [18], number of births
beyond 24 weeks, partner’s (signiﬁcant other’s) smoking
status and health status using the EuroQol ﬁve dimensions
questionnaire (EQ-5D) [26].
Four weeks after randomization, participants were
contacted to complete a questionnaire assessing smoking
status during the past 7 days; we used text messages to
notify them to expect a telephone call and if after several
attempts the call was unsuccessful, we posted and e-mailed
a link to the questionnaire. At 36 weeks gestation
participants were contacted similarly and asked about
smoking behaviour since 4 weeks post-randomization
and in the past 7 days, quit attempts lasting at least
24 hours and use of smoking cessation support. MiQuit
arm participants were also asked their views on the
intervention. Where 7-day complete abstinence from
smoking was reported, we immediately attempted to
validate this biochemically with exhaled-breath carbon
monoxide (CO) readings and/or saliva samples tested for
cotinine, with samples or readings collected at hospital or
home visits. If face-to-face collection was not successful,
postal saliva sample packs were used. Before samples were
donated, participants were asked either verbally or by
questionnaire about smoking status and use of NRT or e-
cigarettes.
To encourage engagement, participants received a £5
shopping voucher for providing data at each of the ﬁrst
three contacts (i.e. £15 maximum); a £10 voucher was
also provided after validation visits. Participants were
informed of how to withdraw from data collection via
postcard, telephone, text or e-mail.
Outcomes
Future trial design parameters
We monitored monthly rates of recruitment and outcome
ascertainment rates, and estimated the validated
abstinence rate in both trial arms combined. We aimed to
enrol 400 participants in 12 months. The key smoking
outcome for a future trial is described below (outcome 1).
Smoking
Smoking measures were: (1) self-reported abstinence from
4 weeks post-randomization until late pregnancy collected
at late pregnancy follow-up (approximately 36 weeks
gestation), with no more than ﬁve cigarettes in total
between the two time-points [27], biochemically validated
at the later time; (2) as 1 but self-report only; (3) self-
reported 7-day point prevalence abstinence at late
pregnancy; (4) as 3 but validated biochemically; (5) self-
reported 7-day point prevalence abstinence at 4 weeks
post-randomization; 6) self-reported 7-day point
prevalence abstinence at both 4 weeks post-randomization
and late pregnancy; and (7) as 6 but validated
biochemically in late pregnancy.
We stated a priori that we anticipated that outcome 1,
continuous abstinence from 4 weeks post-randomization
until 36 weeks gestation, would be most appropriate for a
future RCT to assess MiQuit efﬁcacy deﬁnitively [19]. We
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had concerns about the viability of using this outcome, so a
key objective was to ascertain its feasibility of
measurement. Where participants reported abstinence
but were using NRTor e-cigarettes, CO readings alonewere
used for validation [cut-point of < 9 parts per million (p.p.
m.)]. Otherwise, a saliva cotinine reading of < 10 ng/ml
was also required [28]. Where data from only one
validation method were available, a value below the
relevant cut-point was considered sufﬁcient. Saliva was
analysed by ABS Laboratories Ltd, Hertfordshire.
Economics
As the usual care and intervention groups both had access
to standard NHS smoking cessation and antenatal care, it
was assumed that both groups had equal cost, therefore
the only additional cost would be for delivering MiQuit.
Costs included were the text messages and the annual
running cost. These were based on historical costs
incurred. Costs were calculated at 2014–15 price per year
from a NHS and Personal Social Services perspective.
Sample size
The sample size was justiﬁed primarily on the basis of how
precisely key parameters for the design of a deﬁnitive RCT
could be estimated.With 400 participants (200 per group),
we could estimate the overall recruitment rate to within
±1%, outcome ascertainment rates per treatment group
to within ±4% and combined quit rates for both groups
to within ±3%. Precision estimates for detecting between-
group differences in quit rates were calculated for ranges
of treatment effects [i.e. odds ratio (OR)] and usual care
group quit rates [19] for example, these showed that if a
5% usual care group quit rate occurred in late pregnancy,
with 400 participants the trial would estimate an ORof 1.8
(as noted in a previous review) [12] with 80% conﬁdence
intervals (CIs) of 1.06–3.05) [19].
Statistical analysis
A statistical analysis plan was agreed with the Trial
Steering Committee and published with the trial protocol
[19]. Recruitment and outcome ascertainment rates were
estimated with 95% CIs. For each treatment group, and
for both groups combined, abstinence rates for each
outcome were estimated with 95% Wilson CIs. χ2 tests
(Fisher’s exact tests in cases with small expected
frequencies) were performed to assess the association
between smoking outcomes and treatment group. Firth
(penalized) logistic regression models [29] were then used
to estimate ORs with 95% proﬁle CIs [30] to compare
smoking outcomes between treatment groups, adjusting
for factors used to stratify the randomization via their
inclusion as ﬁxed covariates in each model (trial site,
gestation at randomization). Three additional models for
all seven smoking outcomes were carried out, each
adjusting for one of three baseline variables associated
commonly with smoking in pregnancy (heaviness of
smoking, partner’s smoking status and education)
[31,32], with likelihood ratio tests assessing whether these
improved model prediction. Where convergence of a model
could not be achieved due to low event rates within small
centre sites, these centres were merged to overcome the
issue.
An intention-to-treat (ITT) analysis was used, with all
participants analysed within the treatment group to which
they were randomized and, where missing outcome data,
were assumed smoking [27]. Participants who withdrew
from the study due to miscarriage/stillbirth were included
in the analyses and classed as smoking. Where validation
of abstinence was required, participants not providing a
breath or saliva sample were classed as smoking. Complete
case sensitivity analyses were performed on all smoking
outcomes.
The number of quit attempts since baseline was
compared between groups using a Mann–Whitney U-test.
Participants’ views on the MiQuit intervention were
reported using percentages with 95% Wilson score CIs.
Analyses were carried out in Stata, version 12.
After undertaking the planned analyses, we decided to
generate a Bayes factor from smoking outcome 1, using
an online calculator [33] with an expected effect size of
OR = 1.83 taken from a relevant systematic review [12].
We used a conservative approach for estimation using a
half-normal distribution, where the mode at 0 indicated
no intervention effect and the standard deviation equal to
the expected effect size.
Economic analysis
The main outcomewas the incremental cost per additional
quitter, calculated by dividing the average incremental cost
per participant by the number of additional quitters derived
from smoking outcome 1. Conﬁdence intervals were
generated using bootstrapping with 1000 iterations [34].
RESULTS
During 7 months, we assessed 1181 pregnant smokers for
eligibility and 407 were recruited into the study; 203 were
randomized to MiQuit and 204 to usual care. There was
marked variation in recruitment between the 16 sites
[median 12 participants, interquartile range (IQR) = 34],
with one recruiting no participants. Figure 1 shows
participant ﬂow and reasons for exclusion. At 4 weeks,
295 (72%) participants provided smoking outcome data
(68% MiQuit, 77% usual care). Further attrition in late
pregnancy was fairly minimal, with 261 (64%)
participants providing these outcome data (64% MiQuit,
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65% usual care). Two hundred and thirty (57%) provided
smoking outcome data at both time-points (55% MiQuit,
58% usual care) and 254 (62%) gave data used for
smoking outcome 1 on abstinence between 4 weeks and
late pregnancy (61% MiQuit, 64% usual care). We
obtained validation samples for 37 of 64 (58%) of
participants who reported abstinence at 36 weeks
gestation (56% MiQuit, 61% usual care); with two
(3.1%) and 15 (23%) participants providing only CO or
cotinine readings, respectively.
Table 1 shows baseline participant characteristics by
trial arm; mean age was 26.5 [standard deviation
(SD) = 5.7] years, 92% were white, mean gestation at
enrolment was 14.7 (SD = 4.4) weeks and 60% reported
smoking within 30 minutes of waking; 74% were very or
extremely determined to stop smoking and 40% felt very
or extremely conﬁdent in stopping until their baby was
born. Participants’ characteristics were similar in both
groups, apart from that women randomized into the usual
care group were more likely to reside in the most deprived
(e.g. lower income) areas and have a non-smoking partner.
Smoking outcomes
Table 2 shows cessation rates across and within treatment
groups and provides estimates for MiQuit’s effects. For
smoking outcome 1, 15 participants were classiﬁed as
abstinent; 11 of 203 (5.4%) were in the MiQuit group
and four of 204 (2.0%) in the usual care group (adjusted
OR= 2.70, 95% CI = 0.93–9.35). Estimated treatment
effects for the remaining smoking outcomes also favoured
MiQuit aiding smoking cessation, with ORs ranging from
1.03 to 3.28; those for self-reported abstinence at both
4 weeks post-randomization and in late pregnancy
(smoking outcome 6) reached statistical signiﬁcance.
Adjusting for heaviness of smoking, partner’s smoking
Figure 1 Trial ﬂow. *Includes 17 MiQuit participants without 4-week follow up data; **includes 14 usual care participants without 4-week
follow-up data
Randomized controlled trial of MiQuit 5
© 2017 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
Table 1 Baseline characteristics by treatment group.
MiQuitb
(n = 203)
Usual careb
(n = 204)
Age (years)
Mean (SD) 26.6 (5.7) 26.4 (5.7)
Median (1st Q, 3rd Q) 25.7 (22.1, 30.8) 25.8 (21.9, 29.7)
Min, max 16.9, 40.0 16.6, 41.3
Highest qualiﬁcation
No formal qualiﬁcation 37 (18.2) 44 (21.6)
GCSE or similar 117 (57.6) 106 (52.0)
A level or similar 32 (15.8) 37 (18.1)
Degree or similar 16 (7.9) 13 (6.4)
Declined to answer 1 (0.5) 4 (2.0)
IMD scorea
Quintile 1 13 (6.4) 6 (2.9)
Quintile 2 16 (7.9) 13 (6.4)
Quintile 3 22 (10.8) 21 (10.3)
Quintile 4 53 (26.1) 50 (24.5)
Quintile 5 92 (45.3) 108 (52.9)
missing 7 (3.5) 6 (2.9)
Ethnicity
White 188 (92.6) 185 (90.7)
Indian 0 (0) 0 (0)
Pakistani 3 (1.5) 2 (1.0)
Bangladeshi 0 (0) 0 (0)
Black Caribbean 1 (0.5) 4 (2.0)
Black African 2 (1.0) 1 (0.5)
Black (other) 1 (0.5) 1 (0.5)
Chinese 0 (0) 0 (0)
Other Asian (non-Chinese) 1 (0.5) 0 (0)
Mixed 6 (3.0) 11 (5.4)
Not given 1 (0.5) 0 (0)
Gestation at randomization (weeks)
Mean (SD) 14.6 (4.2) 14.7 (4.5)
Median (1st Q, 3rd Q) 13 (12, 19) 13 (12, 20)
Min, max 4, 23 3, 24
Cigarettes per day before pregnancy
Mean (SD) 15.7 (6.7) 16.4 (6.6)
Median (1st Q, 3rd Q) 15 (10, 20) 15 (10, 20)
Min, max 5, 40 5, 40
Cigarettes per day now
Mean (SD) 9.0 (5.9) 9.4 (6.1)
Median (1st Q, 3rd Q) 8 (5, 10) 10 (5, 10)
Min, max 1, 40 1, 40
Time to ﬁrst cigarette after waking
Within 5 minutes 64 (31.5) 64 (31.4)
6–30 minutes 56 (27.6) 61 (29.9)
31–59 minutes 41 (20.2) 31 (15.2)
1–2 hours 22 (10.8) 29 (14.2)
More than 2 hours 20 (9.9) 19 (9.3)
Frequency of urges to smoke in the past 24 hours
Not at all 3 (1.5) 8 (3.9)
A little of the time 36 (17.7) 37 (18.1)
Some of the time 94 (46.3) 88 (43.1)
A lot of the time 44 (21.7) 42 (20.6)
Almost all the time 16 (7.9) 18 (8.8)
All the time 10 (4.9) 11 (5.4)
Strength of urges to smoke in the past 24 hours
(Continues)
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status and education did not result in any meaningful
changes to the ﬁndings (see Supporting information, Table
S1). In a sensitivityanalysis based onwomenwith complete
outcome data, the ORs were increased for six of the seven
smoking outcomes, including outcome 1 (OR = 3.11,
95% CI = 1.05–10.80) (Supporting information, Table
S2). The number of quit attempts between baseline and late
pregnancy did not differ signiﬁcantly between treatment
groups [MiQuit median 2 (IQR = 1,3), n = 124; usual care
median 1 (IQR = 0,3), n = 130; Mann–Whitney U-test
P = 0.118). The Bayes factor for outcome 1 was 2.23,
meaning that the hypothesis thatMiQuit is effective ismore
than twice as likely to be correct than the hypothesis that it
is not effective. This represents ‘anecdotal evidence’ for
MiQuit having an intervention effect [35].
Use of NHS cessation support
Overall use of ‘non-trial’ cessation support was similar in
both arms (Table 3). When examining speciﬁc types of
support, midwife discussion of smoking was reported by
notably more usual care participants.
Participant evaluations of MiQuit
Among all MiQuit participants, 27 (13%) discontinued
support early (mean days into programme24.1, SD=15.7)
having texted STOP and 13 (6.4%) changed their message
frequency to ‘less’, 11 (5.4%) to ‘more’ and 1 (0.5%) to
‘less’ followed by ‘more’. Among those at late-pregnancy
follow-up who answered the relevant questions, three of
123 (2.4%) reported receiving no text messages and, of
the remaining 120, 97 (81%) reported reading all
messages at least once. Messages relating to fetal
development were rated most frequently (by 35%) as the
most helpful. Table 4 shows that 62% rated the text
messages as quite or extremely helpful, but 14% considered
them annoying; 81% would either ‘probably’ or ‘deﬁnitely’
recommend MiQuit support to a friend or relative.
Economic analysis
The per-participant cost of sending MiQuit texts was
estimated to be £2.95; a mean of 84.1 texts per participant
at 3.5 p per text. The annual running cost of delivering
MiQuit was £339 (£1.67 per participant) and included a
Table 1. (Continued)
MiQuitb
(n = 203)
Usual careb
(n = 204)
No urges 4 (2.0) 6 (2.9)
Slight 58 (28.6) 55 (27.0)
Moderate 78 (38.4) 95 (46.6)
Strong 39 (19.2) 28 (13.7)
Very strong 15 (7.4) 14 (6.9)
Extremely strong 9 (4.4) 6 (2.9)
Have you set a quit date?
No 193 (95.1) 192 (94.1)
Yes 10 (4.9) 12 (5.9)
Are you seriously planning to quit?
No 17 (8.4) 19 (9.3)
Within the next 3 months 68 (33.5) 57 (27.9)
Within the next 30 days 55 (27.1) 59 (28.9)
Within the next 2 weeks 63 (31.0) 69 (33.8)
Number of births beyond 24 weeks
Mean (SD) 1.4 (1.5) 1.4 (1.4)
Median (1st Q, 3rd Q) 1 (0, 2) 1 (0, 2)
Min, max 0, 10 0, 9
Parity
0 births beyond 24 weeks 66 (32.5) 65 (31.9)
1 or more births beyond 24 weeks 137 (67.5) 139 (68.1)
Partner/signiﬁcan other’s smoking status
Smoker 135 (66.5) 128 (62.8)
Non-smoker 34 (16.8) 44 (21.6)
Not applicable (no partner) 34 (16.8) 32 (15.7)
Data are n (%) unless speciﬁed. aIndex of Multiple Deprivation (IMD), Ofﬁce for National Statistics. Quintile 1 (Q) represents least deprivation. bData were
complete for all baseline variables other than IMD score (3.2% missing: no match to home postcode), highest qualiﬁcation (1.2% missing) and ethnicity
(0.25% missing). Similar proportions per trial arm were missing baseline data. SD = standard deviation; GCSE = general certiﬁcate of standard education;
A level =Advanced level.
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virtual reply number (£99) and server/web hosting
including domain name (£240). Thus, the total per-
participant MiQuit cost was £4.62. From Table 2, row 1,
the relevant incremental quit rate estimate was 3.46%,
giving an incremental cost per additional quitter of
£133.53 (95% CI = –£395.78 to 843.62). The probability
of MiQuit being cost-effective was 96.5% if a decision-
maker was willing to pay £10000 to gain an additional
quitter.
DISCUSSION
Statement of principal ﬁndings
This trial demonstrates the feasibility of recruiting
pregnant smokers from multiple UK hospital antenatal
settings to a trial of a text message cessation support
intervention; we met our recruitment target 5 months
earlier than expected. We also found that it was feasible
to measure smoking cessation in participants who were
Table 3 Use of National Health Service (NHS) and other cessation support during trial period.
Outcomea
MiQuit
(n = 124)
Usual care
(n = 130)
Reported use of any stop smoking support n (%) 83 (66.9) 98 (75.4)
Reported use of different types of support n (%)
GP or nurse discussion 20 (16.1) 26 (20.0)
Midwife discussion 45 (36.3) 72 (55.4)
Stop smoking helpline 5 (4.0) 6 (4.6)
NHS Smokefree website 16 (12.9) 15 (11.5)
Other smoking cessation website 7 (5.7) 9 (6.9)
NRT 26 (21.0) 36 (27.7)
Individual NHS behavioural support 9 (7.3) 15 (11.5)
Group NHS behavioural support 3 (2.4) 3 (2.3)
aOutcomes are calculated out of 254 participants with response data at late pregnancy follow-up (124 MiQuit, 130 usual care). NRT = nicotine replacement
therapy; GP = general practitioner.
Table 2 MiQuit treatment effect estimates on seven smoking outcomes.
Outcome Measure
MiQuita
n = 203 (%)
Usual carea
n = 204 (%)
Totala
n = 407 (%) P-valueb
Adjusted odds
ratio (95% CI)c
Abstinence reported from 4 weeks
post-randomization until late pregnancy
(smoking outcome 1)d
Validated 11 (5.42) 4 (1.96) 15 (3.69) 0.064 2.70 (0.93–9.35)
Abstinence reported from 4 weeks
post-randomization until late pregnancy
(smoking outcome 2)d
Self-report 33 (16.26) 33 (16.18) 66 (16.22) 0.983 1.03 (0.61–1.75)
7-day point prevalence abstinence
at late pregnancy (smoking outcome 3)
Self-report 36 (17.73) 28 (13.73) 64 (15.72) 0.267 1.34 (0.79–2.31)
7-day point prevalence abstinence
at late pregnancy (smoking outcome 4)
Validated 15 (7.39) 9 (4.41) 24 (5.90) 0.202 1.67 (0.72–4.03)
7-day point prevalence abstinence
at 4 weeks post-randomization
(smoking outcome 5)
Self-report 15 (7.39) 7 (3.43) 22 (5.41) 0.077 2.11 (0.89–5.46)
7-day point prevalence abstinence
at both 4 weeks post-randomization
and late pregnancy
(smoking outcome 6)
Self-report 13 (6.40) 4 (1.96) 17 (4.18) 0.025 3.16 (1.14–10.69)
7-day point prevalence abstinence
at both 4 weeks post-randomization
and late pregnancy
(smoking outcome 7)
Validated 8 (3.94) 2 (0.98) 10 (2.46) 0.062 3.28 (0.90–17.36)
aAll smoking outcomes are calculated of a total of 407 participants (203MiQuit, 204 usual care). Participants lost to follow-up or with missing outcome data
are assumed to be smoking. bUnadjusted, from a χ
2
test using a two-sided P-value (Fisher’s exact test P-values were used in the case of small expected
frequencies). cModel-based, adjusted by site and gestation at randomization (95% proﬁle conﬁdence intervals reported). dRussell standard criterion (permits
no more than ﬁve cigarettes in total). The criterion for all other smoking outcomes was total abstinence (‘not even a puff ’). CI = conﬁdence interval.
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not expected to set a quit date using a stringent outcome
measure. Using this outcome, we found that 5.4% of
women in the MiQuit group stopped smoking during
pregnancy and 2.0% did in the control group, and this
almost reached statistical signiﬁcance; it is likely, when
tested on a larger scale, that MiQuit will prove to be both
effective and cost-effective for promoting smoking
cessation throughout pregnancy.
Findings in context
The efﬁcacy estimate provided using outcome 1 data
suggests that, compared with usual care, MiQuit may
almost triple the odds of sustained smoking cessation,
but this has limited precision. However, it is the best
estimate yet produced for the probable efﬁcacy of text
messaging used for smoking cessation in pregnancy. It
is also of a similar magnitude to efﬁcacy estimates derived
from ‘deﬁnitive’ trials of similar interventions used by
non-pregnant smokers [36,37] and to that from a smaller
MiQuit trial [18]. Additionally, our estimate for the
probable cost-effectiveness of the intervention is
encouraging; compared with other cessation
interventions, a cost-per-quitter of £134 is low. For
example, although ﬁnancial incentives for smoking
cessation in pregnancy are highly effective [38] and
cost-effective [39], their cost-per-quitter is almost 10
times higher (£1127). Similarly, MiQuit’s cost-efﬁcacy
compares favourably with that of cessation support
delivered by traditional UK smoking cessation services;
the ‘cost-per-person-setting-a-quit-date’ within such
services has been estimated recently as £202 [40].
However, as only 34% of those setting a quit date achieve
longer-term abstinence, the cost-per-quitter [41], inﬂated
accordingly, is probably closer to £600. Although the trial
did not include a formal cost–utility analysis, it is highly
likely that, if cessation is maintained in the longer term,
the calculated ‘cost-per-quitter’ will translate into
longer-term cost-effectiveness. One can assume that
‘quitters’ gain 1.94 quality-adjusted life years (QALYs)
across their life-time [42,43], so by multiplying this value
by the seven additional quitters generated by MiQuit the
incremental QALYs would be 13.58, making the
incremental cost per additional QALY £69.06—even
after inﬂating this ﬁgure to take into account relapse to
smoking [44], this would remain securely within most
accepted cost-effectiveness benchmarks. Finally, it is
noteworthy that the ‘non-text-message’ costs of MiQuit
are ﬁxed, and so ‘per-user’ costs fall as the numbers using
the intervention increase. For example, if MiQuit was
used by 2000 pregnant smokers annually, per-user
‘non-text-message’ costs would be approximately £0.20,
reducing the incremental cost per additional quitter to
approximately £91.
Importantly, systems such as MiQuit could be
particularly useful for the high proportion of pregnant
smokers who currently do not access ‘traditional’methods
of support [45,46]. For example, in the United Kingdom
approximately 83% of pregnant smokers do not use
support offered [46] but, if encouraged, many of these
may use text support.
Strengths and limitations of the study
A limitation is that this RCT did not have a speciﬁed
primary outcome; however, although multiple cessation
outcomes were used, we indicated a priori which was
anticipated to be the most appropriate as a primary
outcome (outcome 1) [19]. Consequently, as we
demonstrated that outcome 1 was feasible to measure, it
is reasonable to use these data to represent MiQuit’s
probable treatment effect. However, caveats to the
interpretation of non-primary RCT outcomes still apply.
Additionally, completeness of follow-up and biochemical
validation rates were not optimal, potentially reducing
statistical power. However, we assumed conservatively that
women lost to follow-up were still smoking [27] and
outcome ascertainment rates were slightly higher in the
usual care group; both factors would tend to attenuate
rather than inﬂate the observed intervention effect.
Table 4 Intervention participant views of and preferences for the MiQuit intervention.
MiQuit
Reported receiving text messages (n = 123) 120 (97.6, 93.1–99.2)
Discontinued the support prematurely by texting ‘STOP’ (n = 203) 27 (13.3, 9.3–18.7)
Rated the text messages as ‘quite’ or ‘extremely’ helpful (n = 120) 74 (61.7, 52.7–69.9)
Rated the text messages as ‘quite or ‘extremely’ annoying (n = 120) 17 (14.2, 9.0–21.5)
Rated the number of text messages received as (n = 120)
‘Far too many’ or ‘a little too many’ 25 (20.8, 14.4–29.2)
‘About right’ 79 (65.8, 56.8–73.9)
‘Not enough’ or ‘not nearly enough’ 16 (13.3, 8.3–20.8)
Would ‘probably’ or ‘deﬁnitely’ recommend the support (n = 120) 97 (80.8, 72.8–86.9)
Data are n %, 95% Wilson conﬁdence interval (CI).
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Consistent with this observation, the complete case
analyses showed stronger intervention effects for most
smoking outcomes, including a statistically signiﬁcant
between-group difference for cessation outcome 1. As with
many RCTs, a further limitation is the unknown
generalizability of ﬁndings to all pregnant smokers. We
did not record data systematically on the numbers or
characteristics of pregnant smokers attending hospital
units during trial recruitment, so we cannot say how
representative the trial sample is although, based on
socio-economic characteristics and smoking rates at pre-
pregnancy and baseline, the sample was generally
representative of women who smoke in pregnancy and
are recruited to trials [10]. Ease of recruitment in antenatal
care settings suggests that there is a substantial cohort of
pregnant smokers who would be likely to use MiQuit if
offered this as part of routine care. Moreover, we have
already shown that 3–4% of pregnant smokers will initiate
MiQuit after receiving a one-page leaﬂet advertising this in
their ‘antenatal booking pack’ [22].
A key strength is that this is the largest RCT to
investigate the efﬁcacy of text message-based, self-help
cessation support which is appropriate for and can be
followed safely by pregnant smokers. The study was
conducted to the highest RCT standards; it employed
remote randomization, those enrolling participants were
blind to treatment allocations and abstinence was
biochemically validated. Additionally, researchers
collecting outcome data were, where possible, blind to
treatment allocations, so outcome ascertainment bias
was minimized. Intervention ﬁdelity was high, 98% of
MiQuit recipients recalled receiving text message support,
and similarities between adjusted and unadjusted analysis
models imply that chance differences in groups’ baseline
characteristics do not explain ﬁndings. Similarly, it seems
unlikely that use of other ‘non-trial’ cessation support
explains ﬁndings; use of such support was very similar in
both groups, except that usual care group women were
more likely to report having discussed smoking with a
midwife. Such support would be expected to increase
cessation in the usual care group, reducing the apparent
efﬁcacy of MiQuit. Overall, therefore, it seems likely that
differences between groups’ smoking rates are due to
MiQuit and not to other factors.
CONCLUSIONS
MiQuit is likely to be an effective smoking cessation
intervention, and further evaluative research is needed. If
further research is conﬁrmatory, pregnancy-orientated
text message systems such as MiQuit could be made
available quickly and cheaply alongside other ﬁrst-line
support options to help pregnant smokers to stop.
Trial registration
ClinicalTrials.gov NCT02043509. Registered 14 January
2014.
Declaration of interests
None.
Acknowledgements
We would like to thank Susanna Mountcastle and Jim
Thornton for their input to the development of the study
and protocol, and to Nottingham Clinical Trials Unit for
their assistance with the study, particularly the
development and management of the database and
randomization. We also gratefully acknowledge members
of the Trial Steering Committee (Paul Aveyard, Jayne
Marshall, Ellinor Olander, Lisa Szatkowski and Kim Watts)
for their input and approval of the ﬁnal trial protocol. This
project was funded by the National Institute for Health
Research (NIHR) under the Programme Grants for Applied
Research programme (RP-PG-0109-10020). The views
and opinions expressed therein are those of the authors
and do not necessarily reﬂect those of the HTA, NIHR,
NHS or the Department of Health. F.N., S.C., K.F., J.E., J.L.
B., S.S., M.U., R.W., S.P. and T.C. are members of the UK
Centre for Tobacco and Alcohol Studies, a UKCRC Public
Health Research: Centre of Excellence. Funding from
British Heart Foundation, Cancer Research UK, Economic
and Social Research Council, Medical Research Council,
and the Department of Health, under the auspices of the
UK Clinical Research Collaboration, is gratefully
acknowledged. The research was supported by the
National Institute for Health Research (NIHR)
Collaboration for Leadership in Applied Health Research
and Care East Midlands at NHS Nottingham City CCG. F.
N., S.C., K.F., J.E., S.S., R.W. and T.C. are members of the
NIHR School for Primary Care Research.
References
1. Pineles B. L., Park E., Samet J. M. Systematic review and
meta-analysis of miscarriage and maternal exposure to
tobacco smoke during pregnancy. Am J Epidemiol 2014;
179: 807–23.
2. Moore E., Blatt K., Chen A., Van H. J., Defranco E. A.
Relationship of trimester speciﬁc smoking patterns and risk
of preterm birth. Am J Obstet Gynecol 2016; 215: 109.e1–6.
3. Flenady V., Koopmans L., Middleton P., Froen J. F., Smith G. C.,
Gibbons K. et al.Major risk factors for stillbirth in high-income
countries: a systematic review and meta-analysis. Lancet
2011; 377: 1331–40.
4. Hogberg L., Cnattingius S. The inﬂuence of maternal
smoking habits on the risk of subsequent stillbirth: is
there a causal relation? Br J Obstet Gynaecol 2007; 114:
699–704.
5. NHS Information Centre. Infant feeding survey 2010: early
results. Leeds: NHS Information Centre; 2011.
10 Felix Naughton et al.
© 2017 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
6. Raisanen S., Kramer M. R., Gissler M., Saari J., Hakulinen-
Viitanen T., Heinonen S. Smoking during pregnancy was up
to 70% more common in the most deprived municipalities—
a multilevel analysis of all singleton births during
2005–2010 in Finland. Prev Med 2014; 67: 6–11.
7. Hawkins S. S., Baum C. F. Impact of state cigarette taxes on
disparities inmaternal smoking during pregnancy.Am J Public
Health 2014; 104: 1464–70.
8. Weden M. M., Miles J. N. Intergenerational relationships
between the smoking patterns of a population-representative
sample of US mothers and the smoking trajectories of their
children. Am J Public Health 2012; 102: 723–31.
9. Leonardi-Bee J., Jere M. L., Britton J. Exposure to parental and
sibling smoking and the risk of smoking uptake in childhood
and adolescence: a systematic review and meta-analysis.
Thorax 2011; 66: 847–55.
10. Chamberlain C., O’Mara-Eves A., Oliver S., Caird J. R., Perlen
S. M., Eades S. J. et al. Psychosocial interventions for
supporting women to stop smoking in pregnancy. Cochrane
Database Syst Rev 2013; Issue 10. Art. No.: CD001055.
https://doi.org/10.1002/14651858.CD001055.pub4.
11. National Institute for Health and Clinical Excellence (NICE).
Quitting Smoking in Pregnancy and Following Childbirth: NICE
Public Health Guidance 26. London: NICE; 2010.
12. Naughton F., Prevost A. T., Sutton S. Self-help smoking
cessation interventions in pregnancy: a systematic review
and meta-analysis. Addiction 2008; 103: 566–79.
13. Whittaker R., McRobbie H., Bullen C., Rodgers A., Gu Y.
Mobile phone-based interventions for smoking cessation.
Cochrane Database Syst Rev 2016; Issue 4. Art. No.:
CD006611. https://doi.org/10.1002/14651858.CD006611.
pub4.
14. Curry S. J., McBride C., Grothaus L., Lando H., Pirie P.
Motivation for smoking cessation among pregnant women.
Psychol Addict Behav 2001; 15: 126–32.
15. Dijkstra A., Ballast K. Personalization and perceived personal
relevance in computer-tailored persuasion in smoking
cessation. Br J Health Psychol 2012; 17: 60–73.
16. Craig P., Dieppe P., Macintyre S., Michie S., Nazareth I.,
Petticrew M. Developing and evaluating complex
interventions: the new Medical Research Council guidance.
BMJ 2008; 337: a1655.
17. Naughton F., Jamison J., Sutton S. Attitudes towards SMS text
message smoking cessation support: a qualitative study of
pregnant smokers. Health Educ Res 2013; 28: 911–22.
18. Naughton F., Prevost A. T., Gilbert H., Sutton S. Randomised
controlled trial evaluation of a tailored leaﬂet and SMS text
message self-help intervention for pregnant smokers (MiQuit).
Nicotine Tob Res 2012; 14: 569–77.
19. Cooper S., Foster K., Naughton F., Leonardi-Bee J., Sutton S.,
Ussher M. et al. Pilot study to evaluate a tailored text message
intervention for pregnant smokers (MiQuit): study protocol
for a randomised controlled trial. Trials 2015; 16: 29.
20. Bandura A. Social Foundations of Thought and Action: A Social
Cognitive Theory. Englewood Cliffs. NJ: Prentice-Hall; 1986.
21. Petty R. E., Cacioppo J. T. Communication and Persuasion:
Central and Peripheral Routes to Attitude Change. New York:
Springer-Verlag; 1986.
22. Naughton F., Cooper S., Bowker K., Campbell K., Sutton S.,
Leonardi-Bee J. et al. Adaptation and uptake evaluation of
an SMS text message smoking cessation programme (MiQuit)
for use in antenatal care. BMJ Open 2015; 5: e008871.
23. Department for Communities and Local Government. English
Indices of Deprivation 2010. 2011. Available at: www.gov.
uk/government/statistics/english-indices-of-deprivation-2010
(accessed 15 August 2016) (Archived at http://www.
webcitation.org/6p8IqysmM).
24. Heatherton T. F., Kozlowski L. T., Frecker R. C., Rickert W.,
Robinson J. Measuring the heaviness of smoking: using
self-reported time to the ﬁrst cigarette of the day and
number of cigarettes smoked per day. Br J Addict 1989;
84: 791–9.
25. West R., Hajek P. Evaluation of the mood and physical
symptoms scale (MPSS) to assess cigarette withdrawal.
Psychopharmacology (Berl) 2004; 177: 195–9.
26. Brooks R. EuroQol: the current state of play. Health Policy
1996; 37: 53–72.
27. West R., Hajek P., Stead L., Stapleton J., West R., Hajek P. et al.
Outcome criteria in smoking cessation trials: proposal for a
common standard. Addiction 2005; 100: 299–303.
28. SRNT Subcommittee on Biochemical Veriﬁcation.
Biochemical veriﬁcation of tobacco use and cessation.Nicotine
Tob Res 2002; 4: 149–59.
29. Firth D. Bias reduction of maximum likelihood estimates.
Biometrika 1993; 80: 27–38.
30. Heinze G., Schemper M. A solution to the problem of
separation in logistic regression. Stat Med 2002; 21:
2409–19.
31. Schneider S., Huy C., Schutz J., Diehl K. Smoking cessation
during pregnancy: a systematic literature review. Drug
Alcohol Rev 2010; 29: 81–90.
32. Riaz M., Lewis S., Coleman T., Aveyard P., West R., Naughton
F. et al. Which measures of cigarette dependence are
predictors of smoking cessation during pregnancy? Analysis
of data from a randomized controlled trial. Addiction 2016;
111: 1656–65.
33. Dienes Z. Make themost of your datawith Bayes. Available at:
http://www.lifesci.sussex.ac.uk/home/Zoltan_Dienes/inference/
Bayes.htm (accessed 15 August 2016) (Archived at http://
www.webcitation.org/6p8Iyt5Ts).
34. Briggs A. H., Wonderling D. E., Mooney C. Z. Pulling cost-
effectiveness analysis up by its bootstraps: a non-parametric
approach to conﬁdence interval estimation. Health Econ
1997; 6: 327–40.
35. Rouder J. N., Speckman P. L., Sun D., Morey R. D., Iverson G.
Bayesian t-tests for accepting and rejecting the null
hypothesis. Psychon Bull Rev 2009; 16: 225–37.
36. Free C., Knight R., Robertson S., Whittaker R., Edwards P.,
Weiwei Z. et al. Smoking cessation support delivered via
mobile phone text messaging (txt2stop): a single-blind,
randomised trial. Lancet 2011; 378: 49–55.
37. Abroms L. C., Boal A. L., Simmens S. J., Mendel J. A., Windsor
R. A. A randomized trial of Text2Quit: a text messaging
program for smoking cessation. Am J Prev Med 2014; 47:
242–50.
38. Tappin D., Bauld L., Purves D., Boyd K., Sinclair L., MacAskill
S. et al. Financial incentives for smoking cessation in
pregnancy: randomised controlled trial. BMJ 2015; 350:
h134.
39. Boyd K. A., Briggs A. H., Bauld L., Sinclair L., Tappin D. Are
ﬁnancial incentives cost-effective to support smoking
cessation during pregnancy? Addiction 2016; 111: 360–70.
40. Venn A., Dickinson A., Murray R., Jones L., Li J., Parrott S.
et al. Effectiveness of a mobile, drop-in stop smoking service
in reaching and supporting disadvantaged UK smokers to
quit. Tob Control 2016; 25: 33–8.
41. Dobbie F., Hiscock R., Leonardi-Bee J., Murray S., Shahab L.,
Aveyard P. et al. Evaluating long-term outcomes of NHS stop
Randomized controlled trial of MiQuit 11
© 2017 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
smoking services (ELONS): a prospective cohort study. Health
Technol Assess 2015; 19: 11–56.
42. Cromwell J., BartoschW. J., Fiore M. C., Hasselblad V., Baker T.
Cost-effectiveness of the clinical practice recommendations in
the AHCPR guideline for smoking cessation. Agency for
Health Care Policy andResearch. JAMA1997; 278: 1759–66.
43. Fiscella K., Franks P. Cost-effectiveness of the transdermal
nicotine patch as an adjunct to physicians’ smoking cessation
counseling. JAMA 1996; 275: 1247–51.
44. Jones M., Lewis S., Parrott S., Wormall S., Coleman T. Re-
starting smoking in the postpartum period after receiving a
smoking cessation intervention: a systematic review.
Addiction 2016; 111: 981–90.
45. Berrueta M., Morello P., Aleman A., Tong V. T., Johnson C.,
Dietz P. M. et al. Smoking patterns and receipt of cessation
services among pregnant women in Argentina and
Uruguay. Nicotine Tob Res 2016; 18: 1116–25.
46. NHS Information Centre. Statistics on NHS stop smoking
Services in England, April 2014 to march 2015. Leeds: Health
and Social Care Information Centre; 2015.
Supporting Information
Additional Supporting Information may be found online in
the supporting information tab for this article.
Table S1 MiQuit treatment effect estimates on seven
smoking outcomes: comparison of baseline model (1) with
models additionally adjusting for (2) heaviness of smoking,
(3) partner’s smoking status and (4) education (all
missing = smoking).
Table S2 MiQuit treatment effect estimates on seven
smoking outcomes: comparison of missing = smoking
and complete case analyses.
Appendix S1 Standard NHS booklet on smoking cessation
provided to all participants (‘baby on the way, quit today’).
Appendix S2 Tailoring characteristics and examples of
MiQuit text messages.
12 Felix Naughton et al.
© 2017 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
